Reed Jobs secures $200M first close for Yosemite’s second cancer fund
What’s the deal? Reed JobsDealroom has a profile for this one. Try Dealroom →, son of Apple co-founder Steve JobsDealroom has a profile for this one. Try Dealroom →, has secured a $200M first close for the second fund of YosemiteDealroom has a profile for this one. Try Dealroom →, a venture firm focused on cancer research, treatment, and prevention. The fund is targeting $350M and plans to back biotech startups and life sciences platforms, Forbes reported.
Yosemite was spun out of Emerson Collective in 2023 and has previously invested with backing from a small group of investors. The new raise marks a step up in scale for the firm’s investing activity.
Why now? The fundraise comes as cancer-focused biotech shows early signs of recovery following a prolonged downturn in venture funding. Advances in areas such as precision medicine and early detection have helped draw capital back to the sector, though selectively.
The timing also reflects a broader shift toward specialist venture funds. As oncology grows more complex and capital-intensive, investors are increasingly backing focused managers rather than generalist firms.
What could go wrong? Cancer investing remains high risk, with long development timelines, heavy capital needs, and frequent clinical failures. Even well-funded companies can struggle to advance therapies through trials, regulatory review, and commercialisation.
Competition for high-quality cancer assets is also intensifying as more specialist funds return to the market. Yosemite will need to differentiate itself in sourcing and supporting companies in a crowded field.
The signal: Yosemite’s first close points to a cautious reopening of capital for life sciences, particularly funds with narrow mandates and long time horizons. It also underscores the growing role of mission-driven venture vehicles operating outside traditional firm-building playbooks.
For cancer-focused startups, the raise is another indication that specialist funding is returning — selectively, and with expectations set for long development cycles rather than fast exits.
Image source:
The Times
J.V.
